Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 9/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31052765 | 1.00 | EGLN2 (0.42) | EGLN2DDR2PGRARTP53 | |
| SCHEMBL26697649 | 0.86 | ALDH1A1 (0.43) | EGLN2ALDH1A1LMNAMEN1CYP1A2 | |
| SCHEMBL26697782 | 0.80 | EGLN2 (0.36) | EGLN2ALDH1A1ENPP1LMNAMAPT | |
| SCHEMBL29309624 | 0.80 | ERBB2 (0.49) | — | |
| SCHEMBL26697667 | 0.78 | CHRM4 (0.39) | ENPP1LMNA | |
| SCHEMBL5952099 | 0.71 | ALDH1A1 (0.62) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL29936085 | 0.68 | EGLN2 (0.38) | EGLN2ALDH1A1LMNAMEN1MAPT | |
| SCHEMBL26697752 | 0.68 | EGLN2 (0.38) | EGLN2ALDH1A1LMNAMEN1MAPT | |
| SCHEMBL26697663 | 0.67 | STK39 (0.45) | PGRARALDH1A1MEN1KMT2A | |
| SCHEMBL27093496 | 0.66 | KDM4E (0.36) | EGLN2ALDH1A1LMNAMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | EGLN2 1183/4885DDR2 842/4885PGR 364/4885 |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | EGLN2 1764/4885DDR2 523/4885PGR 1068/4885 |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | EGLN2 1764/4885DDR2 523/4885PGR 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.